Efficacy and safety of modified baseline BEACOPP regimen in the treatment of advanced Hodgkin's lymphoma
10.3781/j.issn.1000-7431.2010.01.009
- VernacularTitle:改良标准型BEACOPP方案治疗进展期霍奇金淋巴瘤的疗效和安全性
- Author:
Ningjing LIN
;
Yuntao ZHANG
;
Wen ZHENG
;
Xiaopei WANG
;
Yuqin SONG
;
Meifeng TU
;
Lingyan PING
;
Zhitao YING
;
Jun ZHU
- Publication Type:Journal Article
- Keywords:
Hodgkin's disease;
Anti-neoplastic combined chemotherapy protocols;
Modified baseline BEACOPP regimen;
Treatment outcome;
Survival rate
- From:
Tumor
2010;(1):42-47
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the safety and efficacy of a modified baseline BEACOPP regimen(bleomycin+etoposide+adriamycin+cyclophosphamide+vincristine+ procarbazine hydrochloride+ prednisone) in the treatment of advanced Hodgkin 's lymphoma (HL). Methods:From March 2006 to September 2008, 22 previously untreated patients with stages Ⅱ(bulky), Ⅲ and Ⅳ HL were treated with a modified baseline BEACOPP regimen. Each patient was scheduled to receive 6 to 8 cycles of BEACOPP with consolidation radiotherapy to bulky (≥5 cm) or residual disease.Results:There were 11 males and 11 females with a median age of 28 years (15 to 61 years old). Twelve patients (54.5%) had nodular sclerosis HL, and 10(45.5%) had mixed cellularity HL. There were 4 patients in stageⅡ, 7 in stage Ⅲ and 11 in stage Ⅳ. Sixteen patients (72.7%) achieved a complete remission (CR) and 5 patients (22.7%) had partial remission (PR). The total effective rate (CR+PR) was 95.5%. Among all kinds of clinical factors International Prognostic Score (IPS) had significant effect on CR rate (P=0.011). The 1-, 2- and 3-year total survival rates were the same (95.5%); the 1-, 2- and 3-year progression-free survival (PFS) rates were 72.7%, 53.1% and 53.1%, respectively;the 1-, 2- and 3-year disease-free survival rates were 85.9%, 76.4% and 76.4%,respectively. Univariate analysis showed that the gender, IPS and whether achieving CR had significant effects on PFS (P<0.05). The main toxic effects were bone marrow depression and liver injury. Three patients (13.6%) had grade Ⅲ drug-induced lung injury. No treatment-related death was observed.Conclusion:The modified baseline BEACOPP regimen was effective and safe for treatment of newly diagnosed patients with advanced HL.
